Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

Xiaolu Xu; Jincai ZHONG; Hong Lin; Hong Wang; Jinhui Ye; Caiwen Du; Z. Wang; Guorong Zou; Jie Ouyang; Gengsheng Yu; Yongxia Wang; Luzhen Li; Fei Xu; Shien Cui; Mei Xiao; P. Peng

doi:10.1038/s43856-026-01483-z

March 2, 2026Communications MedicineOpen Access

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness and safety of eribulin combined with gemcitabine for recurrent HER2-negative breast cancer.
Phase II, single-arm, open-label trial design
Participants received eribulin and gemcitabine as second-line treatment
Assessment of treatment efficacy and safety through patient monitoring
Eribulin plus gemcitabine demonstrated effectiveness in managing recurrent HER2-negative breast cancer
Treatment was well-tolerated with minimal severe side effects
Provides a potential second-line treatment option for patients with limited choices

Implication

Phase II trial shows effective treatment for HER2-negative breast cancer, suggesting a valuable option for patients.

Abstract

Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xu et al. (2026) studied this question.

synapsesocial.com/papers/69a91d55d6127c7a504c006a https://doi.org/10.1038/s43856-026-01483-z

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading